Vaxart Inc

+0.14 (+2.16%)
Earnings Announcements

Vaxart Reports Q3 Rev Of $265,000 Versus $454,000

Published: 11/12/2020 21:06 GMT
Vaxart Inc (VXRT) - Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Revenue $265,000 Versus $454,000.
Q3 Loss per Share $0.08.
Q3 Revenue Estimate $1.1 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $-0.09 -- Refinitiv Ibes Data (analyst estimates).
Enrollment in Phase 1 for Oral Covid-19 Vaccine Trial Completed.
Significant Viral Load Reduction and Strong Antibody Responses in Covid-19 Hamster Challenge Model.
Vaxart - Believe Vxa-cov2-1 Can Be Conveniently Distributed & Administered Without Need for Cold-chain Storage and Distribution.
Restarting Norovirus Program.
Revenue is expected to be $2.9 Million
Adjusted EPS is expected to be -$0.08

Next Quarter Revenue Guidance is expected to be $0.8 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.